Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I-II Clinical Trial for the Evaluation of Brentuximab Vedotin Plus Etoposide, Solumoderin (Methylprednisolone), High Dose ARA-C (Cytarabine) and Cisplatin in the Transplant and Post-transplant Management for Relapsed or Refractory Classical Hodgkin Lymphoma Patients

Next Previous
Trial Profile

Phase I-II Clinical Trial for the Evaluation of Brentuximab Vedotin Plus Etoposide, Solumoderin (Methylprednisolone), High Dose ARA-C (Cytarabine) and Cisplatin in the Transplant and Post-transplant Management for Relapsed or Refractory Classical Hodgkin Lymphoma Patients

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Cisplatin; Cytarabine; Etoposide; Methylprednisolone
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GELTAMO

    • Most Recent Events

    • 17 Jun 2022 Results assessing long-term results of the phase II trial with the combination of BV and ESHAP [BRESHAP] as 2nd line therapy for RRHL prior to APBSCT presented at the 27th Congress of the European Haematology Association
    • 23 Apr 2019 Status changed from active, no longer recruiting to completed.
    • 15 Feb 2019 The trial has been completed in Spain (End Date;2019-01-14).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top